[HTML][HTML] ONC201 and imipridones: Anti-cancer compounds with clinical efficacy

VV Prabhu, S Morrow, AR Kawakibi, L Zhou, M Ralff… - Neoplasia, 2020 - Elsevier
ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-
inducing compound TIC10. ONC201 appears to act as a selective antagonist of the G …

Metabolic Rewiring in Glioblastoma Cancer: EGFR, IDH and Beyond

A El Khayari, N Bouchmaa, B Taib, Z Wei… - Frontiers in …, 2022 - frontiersin.org
Glioblastoma multiforme (GBM), a highly invasive and incurable tumor, is the humans'
foremost, commonest, and deadliest brain cancer. As in other cancers, distinct combinations …

ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma

ER Jackson, RJ Duchatel, DE Staudt, ML Persson… - Cancer research, 2023 - AACR
Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPG), are the
most lethal of childhood cancers. Palliative radiotherapy is the only established treatment …

Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells

ER Bonner, SM Waszak, MA Grotzer, S Mueller… - Neuro …, 2021 - academic.oup.com
ONC201 is the first member of the imipridone family of anticancer drugs to enter the clinic for
the treatment of diverse solid and hematologic cancers. A subset of pediatric and adult …

Induction of synthetic lethality by activation of mitochondrial ClpP and inhibition of HDAC1/2 in glioblastoma

TTT Nguyen, E Shang, S Schiffgens, C Torrini… - Clinical Cancer …, 2022 - AACR
Purpose: Novel therapeutic targets are critical to unravel for the most common primary brain
tumor in adults, glioblastoma (GBM). We have identified a novel synthetic lethal interaction …

Targeting mitochondrial respiration for the treatment of acute myeloid leukemia

JL Carter, K Hege, HA Kalpage, H Edwards… - Biochemical …, 2020 - Elsevier
Acute myeloid leukemia (AML) is a heterogeneous disease with variable presentation,
molecular phenotype, and cytogenetic abnormalities and has seen very little improvement in …

Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity …

Q Cao, A Hajosch, RE Kast, C Loehmann… - British Journal of …, 2024 - nature.com
Background Glioblastoma represents a brain tumor with a notoriously poor prognosis. First-
line therapy may include adjunctive Tumor Treating Fields (TTFields) which are electric …

Therapeutic drug-induced metabolic reprogramming in glioblastoma

TTT Nguyen, E Shang, MA Westhoff, G Karpel-Massler… - Cells, 2022 - mdpi.com
Glioblastoma WHO IV (GBM), the most common primary brain tumor in adults, is a
heterogenous malignancy that displays a reprogrammed metabolism with various fuel …

Targeting mitochondrial metabolism to reverse radioresistance: an alternative to glucose metabolism

C Bian, Z Zheng, J Su, H Wang, S Chang, Y Xin… - Antioxidants, 2022 - mdpi.com
Radiotherapy failure and poor tumor prognosis are primarily attributed to radioresistance.
Improving the curative effect of radiotherapy and delaying cancer progression have become …

A Comprehensive Biological and Synthetic Perspective on 2-Deoxy-d-Glucose (2-DG), A Sweet Molecule with Therapeutic and Diagnostic Potentials

YS Wijayasinghe, MP Bhansali… - Journal of Medicinal …, 2022 - ACS Publications
Glucose, the primary substrate for ATP synthesis, is catabolized during glycolysis to
generate ATP and precursors for the synthesis of other vital biomolecules. Opportunistic …